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Abstract
Insecticide treatment resistance is considered to be a major factor in the increasing number of infestations by head lice. The large insec-
ticide selection pressure induced by conventional topical pediculicides has led to the emergence and spread of resistance in many parts
of the world. Possible mechanisms of resistance include accelerated detoxification of insecticides by enzyme-mediated reduction, esteri-
fication, oxidation that may be overcome by synergistic agents such as piperonyl butoxide, alteration of the binding site, e.g. altered ace-
tylcholinesterase or altered nerve voltage-gated sodium channel, and knockdown resistance (kdr). Clinical, parasitological and molecular
data on resistance to conventional topical pediculicides show that treatments with neurotoxic insecticides have suffered considerable
loss of activity worldwide. In particular, resistance to synthetic pyrethroids has become prominent, probably because of their extensive
use. As other treatment options, including non-insecticidal pediculicides such as dimeticone, are now available, the use of older insecti-
cides, such as lindane and carbaryl, should be minimized, owing to their loss of efficacy and safety concerns. The organophosphorus
insecticide malathion remains effective, except in the UK, mostly in formulations that include terpineol.
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Introduction
Head lice infestation caused by Pediculus humanus capitis (De
Geer) is the most prevalent human ectoparasitic disease
worldwide. Head lice are haematophagous, wingless insects
belonging to the order Anoplura. Head lice infestation is par-
ticularly frequent among children 3–11 years of age, and may
induce skin irritation, superinfection from scratching, social
stigmatization, and psychological distress [1]. The economic
implications are also substantial. An increased rate of louse
infestation in recent years has been reported from North
and South America, Australia, and a few countries in Europe
and Asia [2–4]. Unlike body lice, which are vectors for
typhus, recurrent fever, and trench fever, head lice are not
known to transmit human infectious pathogens. However,
DNA of Bartonella quintana, a bacterium that causes trench
fever in humans, has been detected in head lice [5–7].
Treatment relies widely on the use of topical insecticides,
such as topical pyrethroids or malathion, that have been rec-
ommended as first-line treatments by some national health
authorities, such as in France. Other options are available,
including topical non-neurotoxic agents such as dimeticone
[8], and physical methods such as bug busting, albeit with
variable results [9]. Other strategies using topical plant-based
compounds or essential oils require further evaluation, even
though some of them are already marketed. Most of the top-
ical pediculicidal treatments are sold over the counter. Oral
treatment with ivermectin is not currently recommended as
a first-line treatment, but could be useful for head louse
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infestation that is unresponsive to insecticide topical treat-
ment [10].
The large insecticide selection pressure induced by con-
ventional pediculicides has led to the emergence and spread
of resistance in many parts of the world. Resistance to insec-
ticides may induce treatment failures, which may result in
chronic infestations requiring additional and episodic treat-
ments. Additional treatments generate costs, possible toxic-
ity, increased inconvenience, and increased insecticide
selection pressure.
Detecting insecticide resistance is not easy. The persis-
tence of living head lice after use of a pediculicide may have
several causes, including: lack of adherence of the patient to
the treatment protocol; incorrect treatment (underdosing or
misusing); lack of ovicidal or residual killing properties of the
product, leading to self-re-infestation; re-infestation (lice
re-acquired after treatment); and authentic resistance of lice
to the pediculicide.
Different patterns of resistance have been described: clini-
cal resistance (i.e. persistence of live lice 1 day after insecti-
cide application); parasitological resistance (i.e. ex vivo
resistance of head lice to pediculicide compounds); and
genetic resistance (i.e. the presence of polymorphisms in
genes associated with ex vivo (and clinical) resistance).
The objective of this review is to describe the current
knowledge about insecticide resistance, considering clinical,
parasitological and molecular data. This review will be limited
to conventional topical pediculicides.
Pyrethroids
Natural pyrethrum was introduced in 1945 (Table 1), and
was later replaced by synthetic derivatives called pyrethroids.
Indeed, pyrethroids, including d-phenothrin and permethrin,
have been registered as pediculicides since the 1970s, and
have been widely available since the 1980s. These com-
pounds have been chemically altered to provide better stabil-
ity to heat and light than natural pyrethrum. Pyrethroids
make up most over-the-counter insecticides sold for head
lice treatment. Pyrethroids are neurotoxins that modify volt-
age-gated sodium channels (VGSCs) by keeping the channel
open for abnormally long periods, leading to spastic paralysis
and death of the lice. Pyrethroids have also a rapid effect in
immobilizing insects, called knockdown, which often pre-
cedes the lethal action.
The exact impact of pyrethroid resistance on effective
control is not known. Pyrethroid resistance in head louse
populations appears to be widespread in various countries,
but varies in intensity and is not yet uniform [11]. In 1983,
the reported clinical efficacy in a study from Panama was
optimal [12] (Table 2). Clinical and parasitological resistance
to pyrethroids was first reported in France (1994), on the
basis of a randomized controlled trial [13]. In this study, the
clinical efficacy of d-phenothrin was only 39% at day 7
(Table 2), which probably reflected an already well-estab-
lished resistance to pyrethroids by head lice in the study
sites. The subsequent main clinical studies, conducted mostly
in the USA and the UK, are summarized in Table 2. Clinical
efficacy assessed on day 7 following application of the com-
pound ranged from 10% [9] to 79.5% [14].
Meanwhile, parasitological resistance was reported from
Europe (Czech Republic [15], the UK [16], and Denmark
[17]), Israel [18], the USA [3,19–21], Argentina [22,23], Japan
[24], and Australia [25]. It should be stressed that resistance
detection with bioassay-based methods is often difficult [26].
The lack of standardization of bioassays makes it difficult to
compare results from different studies [27]. In addition, the
slower kill times or knockdown responses for permethrin,
for example, that were observed in bioassays were not nec-
essarily synonymous with clinical failure, as the insecticide
killed all of the lice, albeit more slowly, at the end of the
test. In clinical practice, longer exposures could result in rel-
atively good efficacy, even on ‘resistant’ head lice.
The molecular events that govern the resistance to
pyrethroids have been at least partly elucidated. Early
reports indicated that permethrin resistance in head lice was
mostly conferred by the recessive kdr trait [20]. Three point
mutations (M815I, T917I, and L920F) in the VGSC a-subunit
gene associated with permethrin-resistant phenotypes were
suggested to be responsible for kdr-type resistance [28].
Sequence analyses of cloned cDNA fragments and genomic
TABLE 1. Main topical formulations of insecticides available
for the treatment of Pediculus capitis
Drug Class
Year
introduced Formulation
Natural
pyrethrum
Pyrethrins 1945 Spray 1%, piperonyl
butoxide (Spray-Pax)
Permethrin Synthetic
pyrethroid
1992 Lotion 0.5% (Nix)
Shampoo 0.3%,
piperonyl butoxide
Cream rinse 1%
Phenothrin Synthetic
pyrethroid
1992 Liquid 0.5% in an
aqueous base
Lotion 0.2%
Mousse 0.5%
Malathion Organophosphorus 1971 Liquid 0.5% in an
aqueous base
Lotion 0.5% in an
alcoholic base, terpineol,
and pine needle oil
(Ovide; Prioderm)
Carbaryl Carbamate 1977 Carbaryl 1% in
an aqueous
base (Carylderm)
Lindane Organochlorine 1960 Shampoo 1%
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DNA fragments from individual louse samples confirmed that
all of the mutations exist en bloc as a resistant haplotype.
Further experiments using site-directed mutagenesis at the
corresponding amino acid sequence positions of the house
fly para-orthologous VGSC a-subunit (Vssc1WT) gene and
heterologous coexpression with the sodium channel auxiliary
subunit of house fly (Vsscb) in Xenopus oocytes showed that
the T917I mutation was the main cause of permethrin resis-
tance in head lice via a kdr-type nerve insensitivity mecha-
nism [23].
The frequency of the resistant kdr-like haplotype is
extremely variable, according to geographical area. A recent
study reported a resistant kdr-like allele frequency of 0.00
for lice from Ecuador, Papua New Guinea, South Korea,
and Thailand [29], whereas lice from Uruguay, the UK and
Australia had a frequency of 1.00. Values ranging from 0.11
to 0.97 were found for Brazil, Denmark, the Czech Repub-
lic, Egypt, and Israel. A study published in 2003 reported a
resistant kdr-like allele frequency ranging from 0.33 to 1.00
in California, Florida, and Texas [11]. Other studies have
also reported variable frequencies: 0.07 in Japan [30], 0.44
in Wales, UK [31], 0.93 in France [32], 0.95 in Denmark
[17], and 0.97 in Canada [33]. Indeed, the widespread use
of pyrethroids may have been a key factor in the selection
of homozygous resistant lice. A recent article suggested
that lice from countries that have easy access to pyre-
throid-based pediculicides may have higher levels of kdr
mutant alleles [29].
The high prevalence of kdr mutant alleles has to be inter-
preted with caution, as the T917I and L920F mutations in
the kdr gene may not be correlated with treatment failure in
prospective studies. Thus, a recent study including a limited
number of lice in Germany reported that the presence of
kdr mutant alleles did not correlate with clinical failure of py-
rethroids [34]. Further clinical trials are required to docu-
ment the relevance of kdr genotyping as predictive of the
clinical outcome of pyrethroid treatment.
Monooxygenase activity may also be partially responsible
for resistance to pyrethroids. Increased monooxygenase
activity was associated with resistance to permethrin in a
study by Gonzalez Audino et al. [35], using biochemical
methods. In this study, piperonyl butoxide (PBO) significantly
enhanced the toxicity of permethrin in four colonies of head
lice, suggesting that this enzymatic system was responsible
for a proportion of pyrethroid resistance. Indeed, the addi-
tion of PBO slows the biotransformation of pyrethrum and
pyrethroids by partially inhibiting insects’ cytochrome P450
enzymes, which significantly improves their effectiveness.
Thus, PBO is a compound included in the formulation of
some pediculicides containing pyrethrins [26]. Permethrin
resistance did not appear to be associated with glutathione-
S-transferase activity in a study conducted in Israel [36].
Malathion
Malathion, a neurotoxic organophosphorus insecticide, binds
irreversibly to acetylcholinesterase when converted to its
oxon form, inhibiting its function, and causing spastic paraly-
sis and death of the lice. Malathion is used in 0.5% formula-
tions, which kill lice rapidly (within 20 min), even though the
duration of application recommended by the FDA and
TABLE 2. Efficacy of topical insecticides for the treatment of Pediculus capitis in main clinical trials
Compound Study site Year
Number
of patients
Cure rate
Day 7 (%)
Cure rate
Day 14 (%) References
Permethrin creme rinse 1% Panama 1983 29 100 97 Taplin 1986 [12]
d-Phenothrin lotion 0.3% France 1992 98 39 Chosidow 1994 [13]
Permethrin creme rinse 1% USA 1996–1999 39 79.5 Hipolito 2001 [14]
Phenothrin lotion 0.5% UK 2003 125 78 Burgess 2005 [58]
Permethrin creme rinse 1% USA Reported in 2004 22 55 Meinking 2004 [59]
Permethrin creme rinse 1% UK Reported in 2005 40 10 Hill 2005 [9]
Permethrin creme rinse 1% USA Reported in 2007 10 50 Meinking 2007 [38]
Malathion lotion 0.5% UK Reported in 1981 108 98 Maunder 1981 [48]
Malathion lotion 0.5% Canada Reported in 1984 29 93 Mathias 1984 [49]
Malathion lotion 0.5% France 1992 95 95 Chosidow 1994 [13]
Malathion lotion 0.5% UK Reported in 2000 40 78 Roberts 2000 [56]
Malathion lotion 0.5% (Ovide) USA Reported in 2007 28 100 Meinking 2007 [38]
Malathion lotion 0.5% UK, Ireland,
France, Israel
2004 327 90 Chosidow 2010 [10]
Malathion lotion 0.5% (Ovide) USA Reported in 2004 41 98 Meinking 2004 [59]
Aqueous malathion 0.5% UK Reported in 2005 30 17 Hill 2005 [9]
Aqueous malathion 0.5% UK 2006 29 34.5 Burgess 2007 [8]
Malathion gel 0.5% USA Reported in 2007 51 100 Meinking 2007 [38]
Lindane lotion 0.5% UK Reported in 1981 97 91 Maunder 1981 [48]
Lindane shampoo 1% UK Reported in 1981 57 86 Maunder 1981 [48]
Lindane shampoo 1% Panama 1983 30 67 43 Taplin 1986 [12]
Lindane shampoo 1% Canada Reported in 1984 33 88 Mathias 1984 [49]
Carbaryl lotion 0.5% UK Reported in 1981 81 100 Maunder 1981 [48]
Carbaryl shampoo 0.5% UK Reported in 1981 64 97 Maunder 1981 [48]
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French health authorities is approximately 8 h. Malathion
was removed from the US market in 1990 (Prioderm; Pur-
due Frederick Company, Norwalk, CT, USA) and in 1994
(Ovide; Medicis Pharmaceutical Corporation, Lakewood, NJ,
USA), owing to problems related to prolonged application
time, flammability, odour, and low sales. Ovide was re-intro-
duced into the US market in 1999, because of the decreased
efficacy reported for other insecticides, such as organochlo-
rines and pyrethroids [37]. Malathion remained continuously
on the market in Europe during the same period. Malathion
is available only as a prescription product in the USA.
Head lice seem to have developed less resistance to mala-
thion than to pyrethroids. In the early 1990s in France, 0.5%
malathion lotion showed higher ovicidal and pediculicidal
activity than 0.3% d-phenothrin lotion in a randomized con-
trolled trial [13]. A more recent randomized, investigator-
blinded study reported the same higher efficacy of 0.5% mal-
athion, either in gel or in Ovide lotion, than of 1% permeth-
rin (Nix, Creme Rinse) [38]. Ovide lotion contains 0.005 g
of malathion per millilitre in a vehicle of isopropyl alcohol
(78%), terpineol, dipentene, and pine needle oil. Interestingly,
30-min, 60-min or 90 min applications of 0.5% malathion gel
were as effective as 8-h to 12-h applications of Ovide lotion.
Using malathion with shorter application times may contrib-
ute to lowering the insecticide selection pressure and reduc-
ing residual concentrations, which may result in delayed
emergence and spread of resistance.
Resistance to malathion was first reported in France [39],
and then in the UK [2], Australia [25], and Denmark [17].
The effectiveness of malathion in a single-blind, randomized
study in the UK was poor, showing cure rates of only 17%
(n = 30) [9]. Low levels of malathion resistance were
reported in 2004 in head lice collected from Florida and
southern California [40]. The difference in efficacy observed
between European countries and the USA may be related to
its continuous use in Europe during the past 30 years, in
contrast to the USA, and/or variations in formulations mar-
keted in the respective continents [41]. Ovide formulation,
which is available only in the USA (an equivalent formulation,
Prioderm, is available in other countries), remains effective
against head lice, even those collected in countries in which
proven resistance to other malathion formulations has been
found. Ovide vehicle (Ovide formulation without malathion)
was first determined to have significant pediculicidal action,
probably because of the isopropanol and terpenes that are
included in this formulation [42]. Ovide formulation contains
a-terpineol in its vehicle, which has its own insecticide effect
according to a report of Downs et al. [43]. This ‘combina-
tion’ may have prevented the emergence and spread of resis-
tance in the USA.
No mechanisms for malathion resistance have been for-
mally reported in head lice. In a variety of insects, malathion
resistance is mainly attributed to elevated esterases. Ester-
ases may contribute to resistance by rapid hydrolysis of
insecticides to their inactive forms or/and by sequestration.
Using bioassays and biochemical methods, Gao et al. [44]
found that esterases, particularly a carboxylesterase, were
involved in the metabolism of malathion in a head louse
strain collected from Bristol, UK, and may be involved in
resistance. Malathion-resistant cases from the UK were pro-
posed to be linked to modified acetylcholinesterase
[2,41,45]. Other putative mechanisms of malathion resistance
in other insects involved elevated metabolism by cyto-
chrome P450 monooxygenases, glutathione-S-transferases,
and phosphotriesterases [44]. In addition, synergist studies
linked malathion-resistant head lice from the USA to multi-
ple-resistance mechanisms [40]. In a study performed in
2000 in schoolchildren from Wales, Thomas et al. [31], using
biochemical methods, did not find any increased activity of
microsomal monooxygenases and total esterases. Gao et al.
[44] did not report altered activities of phosphotriesterases,
glutathione-S-transferases, or acetylcholinesterase.
As a firmly established and unambiguous mechanism of
resistance is currently lacking, no molecular marker of mala-
thion resistance is currently available. Consequently, ex vivo
tests (bioassays) and clinical surveys are required to study
the efficacy of malathion.
Lindane
Lindane (c-hexachlorocyclohexane) is a non-aromatic organo-
chlorine insecticide. When body lice developed widespread
resistance to DDT in the 1950s, owing to kdr, lindane, an
insecticide that acts on the c-aminobutyric acid-gated chlo-
ride channel and not on the VGSC, was introduced, and
quickly became the treatment of choice for head and body
lice. Before the introduction of pyrethroids, lindane was the
most widely used pediculicide in the USA [46]. Available only
by prescription as a 1% shampoo, lindane has neurotoxic
properties resulting in the death of the insect by overstimula-
tion of its central nervous system. However, it has only low
ovicidal activity (30–50% of eggs are not killed) [47].
Resistance has been reported worldwide for many years
[16,46]. Cure rates assessed on day 14 following application
of the 0.5% lotion or 1% shampoo varied from 43% to 91%
in the 1980s [12,48,49] (Table 2).
One per cent lindane shampoo was the least effective ped-
iculicide tested in a study that compared lindane, malathion,
pyrethrin and permethrin efficacy against treatment-resistant
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and treatment-sensitive lice collected in Florida and Panama,
respectively. After 3 h of exposure, only 17% and 61% of lice
from Florida and Panama, respectively, were dead [21].
However, lindane was still effective in 1999 in South Korea,
where another in vitro study revealed a success rate of 93%
[50].
There are concerns that the poor efficacy of lindane will
result in reapplication and overuse that increase the risk of
adverse events, some of which may be serious, including cases
of severe seizures in children. Owing to potential neurotoxic
effects, especially when applied on the whole body surface
area of lesional skin (i.e. scabies) [51] and poor effectiveness
in practice [52], lindane is no longer recommended by the
American Academy of Pediatrics, the Medical Letter, or the
Stafford Report 2008 update, UK. The use of lindane has been
banned in California. Finally, recommendations range from
using it with extreme caution to withdrawing it from the mar-
ket completely [21]. The European Union prohibited the use
of lindane as an insecticide by the end of 2007.
Carbaryl
Carbaryl, introduced in 1977, is a carbamate insecticide that
acts by reversibly inhibiting acetylcholinesterase, leading to
spastic paralysis and death. It is used in 0.5–1% lotions or
shampoos. Its clinical efficacy was reported as being total in
1981 [48], and ranged from 78% to 92% in 1991 [53,54]. A
study performed in 1998 reported two therapeutic failures
(n = 18) with 1% carbaryl lotion in Leeds, UK [45]. Exposure
of head lice to concentrations ranging from 0.8 to 3.2 g per
100 mL of carbaryl showed decreased efficacy, and an enzy-
matic study showed an altered response of acetylcholinester-
ase to carbaryl of head lice from this region [45]. Since
1995, it has been available only on prescription, because of
concerns about possible carcinogenic effects. One per cent
carbaryl in aqueous formulation is still recommended by the
guidelines based on the Stafford Report 2008 update, but it
is no longer manufactured in the UK.
Conclusions
A major factor resulting in increasing numbers of head lice
infestations is insecticide treatment resistance. Resistance is
an acquired trait that an insect pest develops over time
through selective pressure created by prolonged use of insec-
ticides. Some pediculicides have already become ineffective,
and others are likely to meet the same fate. Over the years,
different insecticides have been used to control lice, and resis-
tance patterns vary between countries and between regions
within a country. Ideally, the choice of treatment should
depend on local resistance patterns, but information about
resistance is rarely available. Therefore, molecular markers,
such as kdr-like polymorphisms, may be useful because they
allow the processing of large numbers of insect from many
populations in relatively short periods of time. Unfortunately,
such molecular markers are presently lacking for organophos-
phorus insecticides, and clinical trials remain the reference
standard for the survey of resistance to malathion.
There is strong evidence that head louse populations are
continuing to develop resistance. Unnecessary and excessive
use of pediculicides is frequent. The availability of many over-
the-counter pediculicides makes resistance management by
moderation and/or rotations/mixtures difficult, if not impracti-
cal. When control fails, the usual strategy is to use a different
insecticide, preferably of another class, for the next course of
treatment. Unfortunately, the number of available conven-
tional pediculicides is shrinking, as indicated by the foreseeable
elimination of lindane and carbaryl. Pyrethroids have become
much less effective, and even malathion resistance is probably
evolving upon increased use, as shown in the UK.
As shown by some recent clinical trials, the use of non-
insecticidal pediculicides, such as dimeticone lotion, may be
an effective treatment [8,55]. However, no one can guaran-
tee that head lice will not develop other forms of resistance
to these non-insecticidal pediculicides in the future. In addi-
tion, alternative treatments, such as dimeticone or bug bust-
ing, still have controversial results in comparison with
insecticides in randomized controlled trials [9,56,57].
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